China’s CDK2/4/6 Inhibitor Moves Toward First-Line Therapy: Industry Signals Behind the New Indication Review of Kumoxili

By:DengYue International Business Division

As global breast cancer treatment strategies continue to evolve, drugs targeting cell-cycle regulatory pathways are becoming an important direction in oncology therapy. According to observations from DengYueMed, a global pharmaceutical supply and medical information platform closely tracking innovative drug development, several targeted therapies independently developed in China have recently begun entering the global innovation landscape. Among them, the clinical and regulatory progress of the CDK2/4/6 inhibitor Kumoxili has drawn significant attention within the industry.

Breast cancer remains the most commonly diagnosed malignancy among women worldwide. In China, hormone receptor-positive / HER2-negative (HR+/HER2-) breast cancer accounts for approximately 60–70% of all cases. Currently, multiple authoritative guidelines, including the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines, recommend CDK4/6 inhibitors combined with endocrine therapy as a key treatment strategy for advanced HR+/HER2- breast cancer.

However, with the widespread clinical use of CDK4/6 inhibitors, drug resistance has gradually emerged as a major challenge affecting treatment outcomes. As a result, identifying new molecular targets or therapeutic mechanisms to delay resistance has become a critical focus in breast cancer drug development.

China’s First CDK2/4/6 Inhibitor

Kumoxili was independently developed by Chia Tai Tianqing Pharmaceutical Group and represents a novel triple-target CDK2/4/6 inhibitor.

Unlike conventional CDK4/6 inhibitors, the drug not only inhibits CDK4 and CDK6, but also targets CDK2, theoretically blocking the “escape pathway” used by tumor cells through CDK2 activation.

Within the cell-cycle regulatory process:

● CDK4/6 primarily regulates the G1 phase

● CDK2 plays a crucial role in the G1/S transition and initiation of DNA replication

When tumor cells develop resistance to traditional CDK4/6 inhibitors, the CDK2 pathway is often reactivated, providing a new proliferative driver for cancer cells. Therefore, simultaneous inhibition of CDK2, CDK4, and CDK6 is believed to potentially delay resistance and enhance antitumor activity.

Based on this mechanism, Kumoxili is widely viewed as an important technological advancement in cell-cycle-targeted cancer therapy.

Approved for Second-Line Treatment

In December 2025, China’s National Medical Products Administration (NMPA) approved Kumoxili for clinical use.

The approved indication is:

Kumoxili combined with fulvestrant for patients with HR+/HER2- locally advanced or metastatic breast cancer who have previously received endocrine therapy.

The approval was based on the Phase III CULMINATE-1 clinical trial, which demonstrated a significant improvement in progression-free survival (PFS) with the combination regimen.

With this approval, Kumoxili became the first CDK2/4/6 inhibitor to enter clinical use globally.

First-Line Indication Under Regulatory Review

Following its approval in the later-line setting, Kumoxili’s development strategy is now moving toward first-line treatment.

In March 2025, an application for Kumoxili as first-line therapy for HR+/HER2- locally advanced or metastatic breast cancer was accepted by the Center for Drug Evaluation (CDE) of China’s NMPA.

The submission is primarily supported by the Phase III CULMINATE-2 clinical trial.

The study was conducted across 72 research centers in China, enrolling patients with previously untreated HR+/HER2- advanced breast cancer. The trial compared:

● Kumoxili + fulvestrant

● Placebo + fulvestrant

Key findings showed:

● 44% reduction in the risk of disease progression or death

● Significant improvement in objective response rate (ORR)

● Prolonged duration of response

Notably, consistent benefits were also observed in patients with liver metastases and visceral metastases, groups typically associated with poorer prognoses.

If approved, the new indication could enable Kumoxili to enter the first-line treatment market for breast cancer.

Intensifying Competition in Breast Cancer Targeted Therapy

In recent years, China’s innovative drug development in the field of breast cancer has accelerated significantly. From CDK4/6 inhibitors and PI3K pathway inhibitors to antibody-drug conjugates (ADCs), multiple technological approaches are rapidly expanding therapeutic options.

Industry experts generally believe that future treatment strategies for HR+/HER2- breast cancer will involve:

● Multi-target cell-cycle inhibition

● Precision molecular classification

● Combination therapy strategies

Within this evolving landscape, Kumoxili represents an attempt to move from single CDK4/6 inhibition toward broader multi-target control of the cell cycle.

Industry Perspective

As China’s innovative drug development capabilities continue to improve, an increasing number of novel therapies with original mechanisms are gaining international attention. From targeted therapies to cell-based treatments, Chinese pharmaceutical companies are gradually becoming active participants in the global innovation ecosystem.

By following updates from the global pharmaceutical supply and medical information platform DengYueMed, healthcare professionals and industry organizations can track the development of innovative therapies such as Kumoxili and gain insights into the evolving role of Chinese innovative medicines in the global pharmaceutical industry.